Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

8.680 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Covid Exposed A 'Brain Health Pandemic' — Here's How Biotech Stocks Like Biogen, Sage Therapeutics Could Help ↗

August 11, 2022

Today's depression drugs don't fit many patients' needs. Biotech companies may change that.

Via Investor's Business Daily

Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study ↗

August 02, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Sage Therapeutics: Q2 Earnings Insights ↗

August 02, 2022

Sage Therapeutics (NASDAQ:SAGE) reported its Q2 earnings results on Tuesday, August 2, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeline and Business Progress

August 02, 2022

From Sage Therapeutics, Inc.

Via Business Wire

Where Sage Therapeutics Stands With Analysts ↗

July 11, 2022

Analysts have provided the following ratings for Sage Therapeutics (NASDAQ:SAGE) within the last quarter:

Via Benzinga

8 Analysts Have This to Say About Sage Therapeutics ↗

May 24, 2022

Analysts have provided the following ratings for Sage Therapeutics (NASDAQ:SAGE) within the last quarter:

Via Benzinga

Sage Therapeutics: Q1 Earnings Insights ↗

May 03, 2022

Sage Therapeutics (NASDAQ:SAGE) reported its Q1 earnings results on Tuesday, May 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Scheduled For August 2, 2022 ↗

August 02, 2022

Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion.

Via Benzinga

Expert Ratings For Sage Therapeutics ↗

March 31, 2022

Sage Therapeutics (NASDAQ:SAGE) has observed the following analyst ratings within the last quarter:

Via Benzinga

Sage Therapeutics to Present at Upcoming August Investor Conferences

August 01, 2022

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022

July 19, 2022

From Sage Therapeutics, Inc.

Via Business Wire

R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions

June 29, 2022

Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the...

Via FinancialNewsMedia

Sage Therapeutics to Present at Upcoming June Investor Conferences

June 02, 2022

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics And Biogen Tackle Depression — And Their Stocks Do The Same ↗

June 01, 2022

Sage and Biogen say their MDD drug met every goal in a study of postpartum women.

Via Investor's Business Daily

Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints

June 01, 2022

From Sage Therapeutics, Inc.

Via Business Wire

Analyst Ratings for Sage Therapeutics ↗

May 04, 2022

Over the past 3 months, 7 analysts have published their opinion on Sage Therapeutics (NASDAQ:SAGE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding...

Via Benzinga

Sage Therapeutics to Present at Bank of America Securities 2022 Healthcare Conference

May 04, 2022

From Sage Therapeutics, Inc.

Via Business Wire

The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗

May 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Sage Therapeutics Announces First Quarter 2022 Financial Results and Highlights Pipeline and Business Progress

May 03, 2022

From Sage Therapeutics, Inc.

Via Business Wire

Earnings Scheduled For May 3, 2022 ↗

May 03, 2022

Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter.

Via Benzinga

Sage Therapeutics, Biogen Start Rolling Submission For Zuranolone In Major Depressive Disorder ↗

May 02, 2022

Via Benzinga

The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More ↗

May 02, 2022

Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...

Via Benzinga

Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)

May 02, 2022

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗

April 21, 2022

Sage Therapeutics (NASDAQ:SAGE) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results.

Via Benzinga

Sage Therapeutics to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022

April 19, 2022

From Sage Therapeutics, Inc.

Via Business Wire

The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel ↗

April 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight ↗

April 03, 2022

Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

April 01, 2022

Good morning, investor! It's the last trading day of the week and that means it's time to get into the pre-market stock movers for Friday!

Via InvestorPlace

Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 LUMINARY Study of SAGE-718 in Patients with Mild Cognitive Impairment and Mild Dementia due to Alzheimer’s Disease

April 01, 2022

From Sage Therapeutics, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022 ↗

March 31, 2022

Upgrades

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.